Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: A retrospective analysis of a prospective clinical trial and validation in a population-based registry

The Lancet Oncology

Volumn 16, Issue 9, 2015, Pages 1111-1122

  Pastore, Alessandro ^a   Jurinovic, Vindi ^a   Kridel, Robert ^b   Hoster, Eva ^a   Staiger, Annette M ^c,d,e   Szczepanowski, Monika ^f   Pott, Christiane ^f   Kopp, Nadja ^h   Murakami, Mark ^h   Horn, Heike ^c,d,e   Leich, Ellen ⁱ   Moccia, Alden A ^b   Mottok, Anja ^b   Sunkavalli, Ashwini ^g,h   Van Hummelen, Paul ^g,h   Ducar, Matthew ^g,h   Ennishi, Daisuke ^b   Shulha, Hennady P ^b   Hother, Christoffer ^b   Connors, Joseph M ^b   Sehn, Laurie H ^b   Dreyling, Martin ^a   Neuberg, Donna ^h   Möller, Peter ^j   Feller, Alfred C ^k   Hansmann, Martin L ^l   Stein, Harald ^m   Rosenwald, Andreas ⁱ   Ott, German ^c   Klapper, Wolfram ^f   Unterhalt, Michael ^a   Hiddemann, Wolfgang ^a,n,o   Gascoyne, Randy D ^b   Weinstock, David M ^h   Weigert, Oliver ^a,n,o   more..

^a UNIVERSITY OF MUNICH   (Germany)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c ROBERT BOSCH HOSPITAL   (Germany)

^d DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g Center for Cancer Genome Discovery   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF WÜRZBURG   (Germany)

^j UNIVERSITY OF ULM   (Germany)

^k UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^l GOETHE UNIVERSITY   (Germany)

^m Berlin Reference Center for Lymphoma and Haematopathology   (Germany)

ⁿ INSTITUTE OF EPIDEMIOLOGY   (Germany)

^o GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; MONOCLONAL ANTIBODY;

ADULT; ARID1A GENE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER RISK; CANCER STAGING; CARD11 GENE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREBBP GENE; DNA SEQUENCE; DRUG EFFICACY; EP300 GENE; EZH2 GENE; FAILURE FREE SURVIVAL; FEMALE; FOLLICULAR LYMPHOMA; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; FOLLOW UP; FOXO1 GENE; GENE MUTATION; GENETIC RISK; HIGH RISK POPULATION; HUMAN; KMT2D GENE; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MEF2B GENE; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; TUMOR GENE; VALIDATION STUDY; AGED; DISEASE FREE SURVIVAL; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOMA, FOLLICULAR; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PREDNISONE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84940584440     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00169-2     Document Type: Article

References (35)

1. Anderson JR, Armitage JO, Weisenburger DD Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998, 9:717-720.
2. Hiddemann W, Cheson BD How we manage follicular lymphoma. Leukemia 2014, 28:1388-1395.
3. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011, 377:42-51.
4. Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD Prognostic factors in follicular lymphoma. J Clin Oncol 2010, 28:2902-2913.
5. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004, 104:1258-1265.
6. Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006, 108:1504-1508.
7. Kridel R, Sehn LH, Gascoyne RD Pathogenesis of follicular lymphoma. J Clin Invest 2012, 122:3424-3431.
8. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005, 106:3725-3732.
9. Odejide O, Weigert O, Lane AA, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 2014, 123:1293-1296.
10. Pott C, Brüggemann M, Ritgen M, van der Velden VHJ, van Dongen JJM, Kneba M MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR. Methods in molecular biology 2012, 175-200. Humana Press, Clifton, NJ. J.M. Walker (Ed.).
11. Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014, 505:495-501.
12. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2014, 499:214-218.
13. Reva B, Antipin Y, Sander C Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 2011, 39:e118.
14. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011, 364:2496-2506.
15. Leonard RC, Hayward RL, Prescott RJ, Wang JX The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party. Ann Oncol 1991, 2:655-662.
16. Lopez-Guillermo A, Montserrat E, Bosch F, Terol MJ, Campo E, Rozman C Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994, 12:1343-1348.
17. Federico M, Bellei M, Marcheselli L, et al. Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project. J Clin Oncol 2009, 27:4555-4562.
18. Smith SM Dissecting follicular lymphoma: high versus low risk. Hematology Am Soc Hematol Educ Program 2013, 2013:561-567.
19. Robins JM, Finkelstein DM Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 2000, 56:779-788.
20. Yap DB, Chu J, Berg T, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011, 117:2451-2459.
21. McCabe MT, Graves AP, Ganji G, et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci USA 2012, 109:2989-2994.
22. Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008, 319:1676-1679.
23. Hunter ZR, Xu L, Yang G, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 2014, 123:1637-1646.
24. Trinh DL, Scott DW, Morin RD, et al. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood 2013, 121:3666-3674.
25. Yildiz M, Li H, Bernard D, et al. Activating STAT6 mutations in follicular lymphoma. Blood 2015, 125:668-679.
26. Ying CY, Dominguez-Sola D, Fabi M, et al. MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma. Nat Immunol 2013, 14:1084-1092.
27. Khodabakhshi AH, Morin RD, Fejes AP, et al. Recurrent targets of aberrant somatic hypermutation in lymphoma. Oncotarget 2012, 3:1308-1319.
28. Leich E, Salaverria I, Bea S, et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood 2009, 114:826-834.
29. Bödör C, Grossmann V, Popov N, et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 2013, 122:3165-3168.
30. O'Shea D, O'Riain C, Taylor C, et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood 2008, 112:3126-3129.
31. Cheung KJ, Johnson NA, Affleck JG, et al. Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. Cancer Res 2010, 70:9166-9174.
32. Launay E, Pangault C, Bertrand P, et al. High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis. Leukemia 2012, 26:559-562.
33. Correia C, Schneider PA, Dai H, et al. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood 2015, 125:658-667.
34. McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2013, 492:108-112.
35. Béguelin W, Popovic R, Teater M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013, 23:677-692.